NASDAQ:CING

Cingulate - CING Stock Forecast, Price & News

$1.03

+0.01 (+0.98%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.91
▼
$1.03
50-Day Range: $0.91
▼
$1.85
52-Week Range: $0.66
▼
$2.15

Volume: 50,498 shs
Average Volume: 2.51 million shs
Market Capitalization: $11.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Cingulate (NASDAQ:CING) Stock

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

March 15, 2023 | msn.com

Cingulate stock slumps ~15% on commercialization pact for ADHD drug CTx-1301

March 13, 2023 | msn.com

Cingulate Tanks on Teaming Up with Indegene for ADHD Drug

March 26, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 13, 2023 | bizjournals.com

Cingulate signs agreement to market its first drug candidate

March 13, 2023 | finance.yahoo.com

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

March 10, 2023 | finance.yahoo.com

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

March 10, 2023 | marketwatch.com

Cingulate Shares Slide 19% on Stock Offering

March 10, 2023 | finance.yahoo.com

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 9, 2023 | msn.com

Information overload: Is all this technology bad for your brain?

March 9, 2023 | benzinga.com

EVP and COO at Cingulate Acquires Company Stock Options Worth 40,000 Shares

March 9, 2023 | benzinga.com

Cingulate Chief Executive Officer Awarded $126K Worth of Stock Options

March 5, 2023 | msn.com

New remains of multiple extinct species excavated on Chilean coast

March 4, 2023 | finance.yahoo.com

Why Cingulate Shares Are Trading Higher Today

March 3, 2023 | msn.com

What Is the Default Mode Network?

February 24, 2023 | msn.com

Cingulate Pops after Positive Topline Data

February 24, 2023 | benzinga.com

Thinking about buying stock in Beyond Meat, ACM Research, Farfetch, Protalix Biotherapeutics, or Cingulate?

February 24, 2023 | finance.yahoo.com

Cingulate stock skyrockets after ADHD treatment shows positive trial results

February 24, 2023 | investorplace.com

Why Is Cingulate (CING) Stock Up 72% Today?

February 24, 2023 | msn.com

HUMBL stock dips 2%, cancels reverse stock split

February 23, 2023 | msn.com

Cingulate pops ~76% after hours on trial results for its ADHD treatment drug

February 23, 2023 | finance.yahoo.com

Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD

February 16, 2023 | msn.com

Racism takes a toll on the brain, research shows

February 15, 2023 | marketwatch.com

Postpartum Depression Management Market Share, Size, Share, Industry Trends, Demand, Overview and Forecast 2022 to 2028

February 11, 2023 | msn.com

Researchers identify a potential neural signature of social belonging

February 10, 2023 | msn.com

Obese individuals have reduced grey matter density and functional brain abnormalities, study finds

February 3, 2023 | msn.com

Can Ketamine alleviate depression from chronic pain?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Company Calendar

Today: 3/26/2023
Next Earnings (Estimated): 5/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CING
CUSIP: N/A
CIK: 1862150
Web: www.cingulate.com
Phone: 913-942-2300
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,680,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -174.78%
Return on Assets: -119.80%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 1.12
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.34 per share
Price / Book: 3.03

Miscellaneous

Outstanding Shares: 11,310,000
Free Float: 7,772,000
Market Cap: $11.65 million
Optionable: Not Optionable
Beta: 0.06

Key Executives

Dr. Shane J. Schaffer Pharm.D. (Age 48)
PharmD, CEO & Chairman
Comp: $475k

Mr. Louis G. Van Horn CPA (Age 64)
M.B.A., Exec. VP & CFO
Comp: $380k

Dr. Laurie A. Myers M.B.A. (Age 66)
Ph.D., Exec. VP & COO
Comp: $400k

Mr. Craig S. Gilgallon Esq. (Age 50)
Exec. VP, Gen. Counsel & Board Sec.
Comp: $380k

Dr. Raul R. Silva M.D. (Age 65)
Exec. VP & Chief Science Officer

Thomas Dalton
Head of Investor & PR

Dr. Matthew N. Brams M.D. (Age 59)
Exec. VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CING Stock - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CING shares.
View CING analyst ratings or view top-rated stocks.
How have CING shares performed in 2023?: Cingulate's stock was trading at $1.00 at the beginning of 2023. Since then, CING stock has increased by 3.0% and is now trading at $1.03.
View the best growth stocks for 2023 here.
When is Cingulate's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CING earnings forecast.
When did Cingulate IPO?: (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

What is Cingulate's stock symbol?: Cingulate trades on the NASDAQ under the ticker symbol "CING."
Who are Cingulate's major shareholders?: Cingulate's stock is owned by many different institutional and retail investors. Top institutional investors include HighTower Advisors LLC (0.30%). Insiders that own company stock include Craig S Gilgallon, Curtis Medeiros, Gregg Wm Givens, Horn Louis G Van, Jennifer L Callahan, Laurie Myers, Peter J Werth and Shane J Schaffer.
View institutional ownership trends.
How do I buy shares of Cingulate?: Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cingulate's stock price today?: One share of CING stock can currently be purchased for approximately $1.03.
How much money does Cingulate make?: Cingulate (NASDAQ:CING) has a market capitalization of $11.65 million. The company earns $-17,680,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.
How can I contact Cingulate?: The official website for the company is www.cingulate.com. The company can be reached via phone at 913-942-2300 or via email at ir@cingulate.com.

This page (NASDAQ:CING) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial